LRRC37A2 Activators
Forskolin, a well-known adenylyl cyclase activator, increases intracellular concentrations of cAMP, which in turn can enhance protein kinase A (PKA) activity. PKA has numerous cellular targets and can modulate gene expression, potentially affecting the levels of LRRC37A2. Retinoic acid, a metabolite of vitamin A, functions by activating nuclear retinoic acid receptors. These receptors are transcription factors that, once activated, can bind to DNA and modulate gene transcription. Through this mechanism, retinoic acid has the capacity to alter the expression of a multitude of genes, including possibly those involved in the regulation of LRRC37A2.
Epigenetic modulators such as 5-Azacytidine and Trichostatin A impact gene expression by modifying DNA and histone structures, respectively. 5-Azacytidine inhibits DNA methyltransferases, leading to DNA demethylation and potential re-expression of silenced genes. Trichostatin A, on the other hand, inhibits histone deacetylases, promoting a more open chromatin state conducive to gene transcription, which may include genes related to LRRC37A2. Activators such as PMA and EGF stimulate protein kinase C and EGF receptors respectively, initiating signaling cascades that can lead to the alteration of gene expression profiles, including those of LRRC37A2. Similarly, IGF-1's interaction with its receptor can trigger signaling pathways that influence gene expression. Sodium butyrate, another histone deacetylase inhibitor, fosters transcriptional activation, potentially increasing the expression of genes related to LRRC37A2. Compounds like LY294002, AICAR, SB203580, and Rapamycin target key signaling pathways such as PI3K/Akt, AMPK, p38 MAP kinase, and mTOR, respectively. By modulating these pathways, these chemicals can indirectly affect the expression and function of numerous proteins, including LRRC37A2.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid activates nuclear retinoic acid receptors, which can bind to DNA and affect gene transcription. This action may lead to alterations in the expression levels of a wide array of genes, including those involved in the regulation of LRRC37A2 expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
As an inhibitor of DNA methyltransferases, 5-Azacytidine reduces DNA methylation, a key epigenetic mechanism that silences gene expression. The demethylation can result in the upregulation of genes, which includes the potential to increase the expression of LRRC37A2. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
By inhibiting histone deacetylases, Trichostatin A causes hyperacetylation of histones, resulting in a relaxed chromatin structure and promoting transcriptional activation. This epigenetic modification can lead to the expression of a variety of genes, potentially including those associated with LRRC37A2 activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC) which is involved in numerous signaling pathways. PKC activation can lead to changes in phosphorylation of proteins that regulate gene expression, which in turn may influence LRRC37A2 expression levels. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate acts as a histone deacetylase inhibitor, leading to increased acetylation of histones and a consequent loosening of chromatin structure. This facilitates transcriptional activation of many genes, with the potential to affect those involved in LRRC37A2 expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter the PI3K/Akt pathway, a key signaling route that affects various cellular processes, including transcription. By modulating this pathway, LY294002 can indirectly influence the expression of numerous genes, potentially including those related to LRRC37A2 activity. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR activates AMP-activated protein kinase (AMPK), which is a regulator of cellular energy homeostasis. AMPK activation can affect transcription factors and coactivators, potentially leading to changes in gene expression, including the regulation of LRRC37A2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase, which is involved in response to stress and cytokines. Modulation of p38 MAPK activity can lead to changes in gene expression, and this may include genes associated with the regulation of LRRC37A2. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which plays a significant role in protein synthesis and cell growth. By inhibiting mTOR, rapamycin can alter the expression and function of numerous proteins and may have an indirect effect on the regulation of LRRC37A2 expression. | ||||||